These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 9102455)

  • 1. Deprenyl--past and future. Proceedings of a symposium. Lake Starnberg, Bavaria, 1995.
    J Neural Transm Suppl; 1996; 48():1-112. PubMed ID: 9102455
    [No Abstract]   [Full Text] [Related]  

  • 2. Selegiline in Parkinson's disease.
    Calne DB
    BMJ; 1995 Dec; 311(7020):1583-4. PubMed ID: 8555790
    [No Abstract]   [Full Text] [Related]  

  • 3. Selegiline's neuroprotective capacity revisited.
    Riederer P; Lachenmayer L
    J Neural Transm (Vienna); 2003 Nov; 110(11):1273-8. PubMed ID: 14628191
    [No Abstract]   [Full Text] [Related]  

  • 4. The fabulous neuroprotection of selegiline: memoir and prospectus.
    Landau WM
    J Child Neurol; 2010 Oct; 25(10):1302-4. PubMed ID: 20940135
    [No Abstract]   [Full Text] [Related]  

  • 5. DATATOP-study: significance of its results in the treatment of Parkinson's disease.
    Schneider E
    J Neural Transm Suppl; 1995; 46():391-7. PubMed ID: 8821074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug therapy of Parkinson's disease].
    Myllylä V
    Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076
    [No Abstract]   [Full Text] [Related]  

  • 7. [What strategies are recommended for early stage disease? Other treatments].
    Damier P
    Rev Neurol (Paris); 2000; 156 Suppl 2 Pt 2():105-8. PubMed ID: 10916044
    [No Abstract]   [Full Text] [Related]  

  • 8. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
    Jenner P
    Neurology; 2004 Oct; 63(7 Suppl 2):S13-22. PubMed ID: 15477581
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.
    Jost WH; Friede M; Schnitker J
    Eur Rev Med Pharmacol Sci; 2014 Nov; 18(22):3349. PubMed ID: 25491607
    [No Abstract]   [Full Text] [Related]  

  • 10. Selegiline, pregnancy, and Parkinson's disease.
    Kupsch A; Oertel WH
    Mov Disord; 1998 Jan; 13(1):175-6. PubMed ID: 9452347
    [No Abstract]   [Full Text] [Related]  

  • 11. Reexamination of the TEMPO Study.
    Shults CW
    Arch Neurol; 2005 Aug; 62(8):1320; author reply 1321. PubMed ID: 16087778
    [No Abstract]   [Full Text] [Related]  

  • 12. Neuroprotection by selegiline and other MAO inhibitors.
    Stern G
    J Neural Transm Suppl; 1998; 52():99-107. PubMed ID: 9564613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal selegiline (Emsam).
    Med Lett Drugs Ther; 2006 May; 48(1235):41-2. PubMed ID: 16770292
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical trials of neuroprotection for Parkinson's disease.
    LeWitt PA
    Neurology; 2004 Oct; 63(7 Suppl 2):S23-31. PubMed ID: 15477583
    [No Abstract]   [Full Text] [Related]  

  • 15. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.
    Knoll J
    Pharmacol Toxicol; 1998 Feb; 82(2):57-66. PubMed ID: 9498233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAO-B inhibitor know-how: back to the pharm.
    Lewitt PA
    Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057
    [No Abstract]   [Full Text] [Related]  

  • 17. [Use of iumeks in the combined therapy of parkinsonism patients ].
    Man'kovskiĭ NB; Karaban' IN; Mialovitskaia EA
    Vrach Delo; 1987 Aug; (8):100-2. PubMed ID: 3120415
    [No Abstract]   [Full Text] [Related]  

  • 18. Current status of selegiline as a neuroprotective agent in Parkinson's disease.
    Olanow CW; Mytilineou C; Tatton W
    Mov Disord; 1998; 13 Suppl 1():55-8. PubMed ID: 9613720
    [No Abstract]   [Full Text] [Related]  

  • 19. Neuroprotection for Parkinson's disease: prospects and promises.
    Olanow CW; Schapira AH; Agid Y
    Ann Neurol; 2003; 53 Suppl 3():S1-2. PubMed ID: 12666093
    [No Abstract]   [Full Text] [Related]  

  • 20. [The early therapy challenge].
    Reichmann H
    Krankenpfl J; 2005; 43(7-10):240. PubMed ID: 16515310
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.